Nasdaq 100 Futures Regain Footing in Wake of Tech Share Selloff
- AstraZeneca drug trial halted on possible safety issues
- Tech shares fueled rout in American equity markets Tuesday
This article is for subscribers only.
Nasdaq 100 futures advanced Wednesday while S&P 500 contracts inched higher as investors took a breather from a rout in U.S. technology shares and factored in a report that a Covid-19 vaccine trial was paused.
Nasdaq 100 futures gained 1.6% as of 10:20 a.m. in London, after reversing an earlier slide of 1.1%. Contracts on the S&P 500 climbed 0.7%. Shares in exchange-traded funds that track the S&P 500 and Nasdaq 100 indexes had turned sharply lower after AstraZeneca Plc has put on hold a study testing a Covid-19 vaccine. The company’s shares were down 0.9% in London.